secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-08-04T12:25:32+00:00
Accession:  0001104659-26-090094
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reports Q2 2026 results; in-licenses two late-stage assets, ciprocopan approved in China, raises $115M
--------------------------------------------------------------------------------

- In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.
- Completed follow-on offering in July 2026 raising $115M gross proceeds, extending cash runway into 1H 2029.
- Cash and equivalents $22.2M as of June 30, 2026, down from $31.6M at Dec 31, 2025.
- Net loss for Q2 2026 was $7.0M vs $6.3M in Q2 2025; R&D expenses rose to $4.7M from $3.6M.
- U.S. IND submission for ciprocopan expected in 4Q2026; NXP200 IND also expected in 4Q2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/0001104659-26-090094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer